# Extended Access of Momelotinib in Adults With Myelofibrosis

> **NCT03441113** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 237 (actual)

## Conditions studied

- Neoplasms
- Post-polycythemia Vera Myelofibrosis (Post-PV MF)
- Primary Myelofibrosis (PMF)
- Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Primary Myelofibrosis

## Interventions

- **DRUG:** MMB

## Key facts

- **NCT ID:** NCT03441113
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-03
- **Primary completion:** 2026-12-11
- **Final completion:** 2026-12-11
- **Target enrollment:** 237 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03441113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03441113, "Extended Access of Momelotinib in Adults With Myelofibrosis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03441113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*